Experimental MS therapy reduces damage, helps repair myelin in mice
GV300 targets ROCK2, a protein involved in inflammation and nerve cell health
Written by |
Experimental MS therapy GV300 reduced inflammation and myelin damage and promoted myelin repair in preclinical mouse studies. (Photo from iStock)
- Progressive multiple sclerosis (MS) involves inflammation, myelin damage, nerve cell injury, and worsening disability over time.
- In MS, abnormal immune activity damages myelin, disrupting communication between nerve cells and contributing to neurological symptoms.
- In mouse models of MS, experimental therapy GV300 reduced inflammation and myelin damage and promoted myelin repair by targeting ROCK2.
GV300, an experimental treatment being developed by Graviton Bioscience for progressive forms of multiple sclerosis (MS), reduced inflammation and myelin damage and promoted myelin repair in mouse models of the disease.
The findings, presented at the Neuroscience 2026 conference, suggest that targeting a protein called ROCK2 could help address several processes involved in MS, including inflammation, myelin damage, and nerve cell injury.
“These findings provide compelling preclinical evidence that selective, brain-penetrant ROCK2 inhibition, such as GV300, may offer a differentiated approach by going beyond controlling inflammation, while simultaneously targeting cellular pathways involved in myelin repair and neuronal health,” Samuel D. Waksal, PhD, founder and CEO of Graviton, said in a company press release.
Myelin damage contributes to MS symptoms and disability
Myelin is a fatty substance that surrounds nerve fibers, helping them transmit electrical signals more efficiently. In MS, an abnormal immune response damages myelin in the brain and spinal cord, disrupting communication between nerve cells and contributing to MS symptoms.
Although available MS treatments can reduce inflammation and disease activity, they are less effective at addressing the processes that drive disability progression, especially when it occurs independently of relapses. Treatments that help repair damaged myelin are also needed, as they could potentially help patients regain lost function.
“Patients with progressive multiple sclerosis continue to have limited treatment options, particularly when disease progression occurs independently of relapses,” Waksal said. “There remains a major need for therapies that go beyond controlling peripheral inflammation and address the mechanisms underlying demyelination, neuronal injury, and progressive disability.”
GV300 is designed to block ROCK2, a protein that regulates immune cell activity and cellular processes involved in neurological function and repair. According to Graviton, the experimental therapy is highly selective for ROCK2 and can cross from the bloodstream into the brain, potentially allowing it to act on disease-related processes there.
In the new preclinical studies, investigators tested GV300 in two mouse models of myelin damage.
One was experimental autoimmune encephalomyelitis (EAE), a commonly used model of MS in which researchers trigger an immune response that causes inflammation and myelin damage. In this model, oral treatment with GV300 lowered clinical disease scores, indicating less severe disease. It also reduced myelin damage and inflammation in the spinal cord, as well as levels of biomarkers associated with neurodegeneration (nerve cell damage).
GV300 promotes myelin repair in a second mouse model
The researchers also tested GV300 in a cuprizone-induced model, in which exposure to a toxic chemical triggers myelin damage without an autoimmune response. In this model, treatment promoted myelin repair, suggesting that the potential effects of ROCK2 inhibition may go beyond suppressing the immune system.
Additional laboratory studies indicated that selective ROCK2 inhibition enhanced myelin production by oligodendrocytes, cells in the brain and spinal cord that make myelin. Selective ROCK2 inhibition also promoted the growth of neurites (nerve cell projections) and helped microglia, immune cells in the central nervous system, clear debris from damaged myelin.
“These findings suggest that selective ROCK2 inhibition has the potential to address multiple components of MS biology simultaneously,” said Julien Moretti, PhD, director of Graviton’s translational medicine group. “In our preclinical and ex vivo studies, we observed not only a reduction in disease-associated inflammation, but also direct effects on oligodendrocytes, microglia and neurons that are consistent with remyelination and restoration of [a healthy balance in the brain and spinal cord].”
“This combination may be particularly important in progressive MS, where neurodegeneration and the failure of effective repair become increasingly important drivers of the disease, while neuroinflammation becomes less dominant,” added Alexandra Zanin-Zhorov, PhD, senior vice president of Graviton.
Leave a comment
Fill in the required fields to post. Your email address will not be published.